Trial reportAddictive behaviors2014
The impact of pre-cessation varenicline on behavioral economic indices of smoking reinforcement.
Trial report in Addictive behaviors, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 5 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 5 syntheses or guidelines pooled it.
- Nicotine receptor partial agonists for smoking cessation.The Cochrane database of systematic reviews · 2023Pooled it
- Experimental manipulations of behavioral economic demand for addictive commodities: a meta-analysis.Addiction (Abingdon, England) · 2020Pooled it
- Sensitivity of hypothetical purchase task indices when studying substance use: A systematic literature review.Preventive medicine · 2019Pooled it
- Behavioral economic tobacco demand in relation to cigarette consumption and nicotine dependence: a meta-analysis of cross-sectional relationships.Addiction (Abingdon, England) · 2019Pooled it
- Nicotine receptor partial agonists for smoking cessation.The Cochrane database of systematic reviews · 2016Pooled it
- Do lab-based assessments of pretreatment smoking reinforcement and cue-specific craving predict smoking cessation with varenicline?Psychology of addictive behaviors : journal of the Society of Psychologists in Addictive Behaviors · 2025Trial
- Effects of episodic future thinking on reinforcement pathology during smoking cessation treatment among individuals with substance use disorders.Psychopharmacology · 2022Trial
- The impact of three weeks of pre-quit varenicline on reinforcing value and craving for cigarettes in a laboratory choice procedure.Psychopharmacology · 2021Trial
- Effects of varenicline versus transdermal nicotine replacement therapy on cigarette demand on quit day in individuals with substance use disorders.Psychopharmacology · 2017Trial
- The Relative Reinforcing Value of Menthol Among Young Adult Cigarette Smokers: Results From a Behavioral Choice Task.Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco · 2025Article
- Behavioral economic measurement of cigarette demand: A descriptive review of published approaches to the cigarette purchase task.Experimental and clinical psychopharmacology · 2020Review
- Relating individual differences in nicotine dependence severity to underpinning motivational and pharmacological processes among smokers from vulnerable populations.Preventive medicine · 2020Article
- Behavioral economic demand as a unifying language for addiction science: Promoting collaboration and integration of animal and human models.Experimental and clinical psychopharmacology · 2020Review
- Behavioral Economic Research in Addiction as an Area of Growth for the Experimental Analysis of Behavior.Behavior analysis (Washington, D.C.) · 2018Article
- Simulating demand for cigarettes among pregnant women: A Low-Risk method for studying vulnerable populations.Journal of the experimental analysis of behavior · 2017Article
- Comparing exponential and exponentiated models of drug demand in cocaine users.Experimental and clinical psychopharmacology · 2016Article
- Persistence and amplitude of cigarette demand in relation to quit intentions and attempts.Psychopharmacology · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundVarenicline was developed to aid smoking cessation by reducing smoking reinforcement. The present study tests this reinforcement-reduction hypothesis among smokers preparing to quit.
methodAfter a one-week baseline, treatment-seeking smokers were randomized to receive three weeks of varenicline or placebo (Weeks 2-4). During each of the four weeks of the study, smokers completed a hypothetical cigarette purchase task (CPT) via handheld devices in their natural environment. Behavioral economic measures of simulated smoking if cigarettes were free (demand intensity), sensitivity of consumption to increasing price (elasticity), and price at which purchases would drop to 0 (breakpoint) were estimated.
resultsThe exponential demand equation fit the purchase task data well across subjects and time. As predicted, demand intensity decreased and sensitivity to price (elasticity) increased over time. However, changes in demand intensity did not differ by treatment group. Contrary to our hypothesis that varenicline would increase sensitivity to price, the placebo group tended to become more elastic in their purchases during Weeks 2 and 3; the groups did not differ in elasticity at Week 4. Breakpoint did not vary by group, time, or their interaction.
conclusionSimulated smoking demand can be validly assessed in the natural environment of treatment-seeking smokers. Simulated demand indices of smoking reinforcement diminished as smokers approached their target quit date. However, there was no evidence that varenicline facilitated these changes over a three-week period, leaving open the mechanisms by which varenicline reduces smoking rate prior to cessation and improves long-term abstinence.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.